|
Daily Medical Update
Urticaria and angioedema
Monday, August 03, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Journal of allergy and clinical immunology (2025) - Systematic review and network meta-analysis
Key Findings
- Across 93 studies with 11,398 participants, standard-dose omalizumab 300 mg every 4 weeks and remibrutinib were among the most effective options for improving multiple patient-important outcomes.
- Cyclosporine may improve urticaria activity but may increase adverse events, while dupilumab improved urticaria activity with uncertain quality-of-life and angioedema effects.
📋 Practice Implication: For antihistamine-refractory chronic urticaria, prioritize omalizumab 300 mg or remibrutinib before conventional immunosuppressants when efficacy and tolerability are both central.
|
Asian Pacific journal of allergy and immunology (2025) - Clinical practice guideline
Key Findings
- Up to 50% of patients remained refractory even at quadruple doses of second-generation H1 antihistamines, with meaningful quality-of-life and mental well-being impact.
- The guideline provides a standardized step-wise algorithm intended to improve clinical efficacy and reduce socioeconomic burden in H1 antihistamine-resistant chronic spontaneous urticaria.
📋 Practice Implication: Use a structured escalation pathway for persistent CSU rather than repeated antihistamine cycling when symptoms continue despite high-dose second-generation H1 blockade.
|
JAMA dermatology (2026) - Phase 3 randomized clinical trials
Key Findings
- In CUPID-C, dupilumab improved ISS7 versus placebo at week 24 with least squares mean changes of -8.64 vs -6.10, a -2.54 point difference.
- Dupilumab improved UAS7 versus placebo at week 24 with least squares mean changes of -15.86 vs -11.21, while treatment-emergent adverse events were 53.5% vs 55.9% in pooled data.
📋 Practice Implication: Consider dupilumab for anti-IgE-naive CSU uncontrolled on H1 antihistamines, especially when type 2 comorbidity or avoidance of IgE-targeted therapy influences selection.
|
The Journal of allergy and clinical immunology (2025) - Phase 3 randomized studies
Key Findings
- At week 52, patients randomized to remibrutinib had sustained UAS7 improvements from baseline of -23.22 in REMIX-1 and -22.98 in REMIX-2.
- Patients switching from placebo to remibrutinib at week 24 improved as early as 1 week after transition, and exposure-adjusted serious adverse events remained equivalent to the 24-week analysis.
📋 Practice Implication: Remibrutinib offers an oral targeted option with durable one-year symptom control for CSU patients still symptomatic on second-generation H1 antihistamines.
|
The Journal of dermatological treatment (2025) - Network meta-analysis of randomized controlled trials
Key Findings
- Across 15 randomized trials with 4,913 patients, omalizumab 300 mg improved UAS7, ISS7, symptom remission, and disease control most at weeks 12 and 24.
- Remibrutinib had the greatest DLQI improvement and second-highest UAS7 reduction, while dupilumab provided sustained itch relief but delayed efficacy.
📋 Practice Implication: When choosing among advanced CSU therapies, omalizumab 300 mg remains the best-supported first advanced agent, with remibrutinib a strong alternative when quality-of-life gain or oral dosing is prioritized.
|
|
💡
Summary
Recent high-impact evidence for chronic urticaria emphasizes biologic and targeted oral therapy after inadequate control with second-generation H1 antihistamines. Omalizumab 300 mg and remibrutinib show the strongest comparative efficacy signals, while dupilumab adds an evidence-based option for anti-IgE-naive patients and guideline work standardizes escalation for H1 antihistamine-resistant disease.
|
|